المؤلفون: Kai Wang, Xiangdong Zhou, Qi Wang, Xiaoxia Cui, Xiaoyu Zhang, Chunxue Bai, Li Zhang, Jian Zhang, Jianping Zhao, Peng Song, Xiaoju Zhang, Faguang Jin, Yao Yu, Li Bai, Xiaoli Zhu, Yanbin Zhou, Chengzhi Zhou

المصدر: Thoracic Cancer

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, Adolescent, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, NSCLC, Multi‐omics, B7-H1 Antigen, Young Adult, Study Protocol, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, PD‐1/PD‐L1 inhibitor, Carcinoma, Non-Small-Cell Lung, PD-L1, Internal medicine, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, predictive biomarker, Lung cancer, Aged, Response rate (survey), biology, business.industry, General Medicine, Immunotherapy, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Immunohistochemistry, Female, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adb9f8018da18f4739ee639337e1c7efTest
https://doi.org/10.1111/1759-7714.13078Test

المؤلفون: Ao Sun, Elaine Lai-Han Leung, Pei-Yu Yan, Ze-Bo Jiang, Ju-Min Huang, Jia-Xin Li, Run-Ze Li

المصدر: Integrative Cancer Therapies, Vol 18 (2019)
Integrative Cancer Therapies

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Durvalumab, Lung Neoplasms, medicine.medical_treatment, Population, Programmed Cell Death 1 Receptor, review, Antineoplastic Agents, Pembrolizumab, Review Article, lcsh:RC254-282, B7-H1 Antigen, Targeted therapy, Avelumab, 03 medical and health sciences, 0302 clinical medicine, non–small cell lung cancer, combinational therapy, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Medicine, Chinese Traditional, Lung cancer, education, education.field_of_study, business.industry, PD-1/PD-L1 inhibitor, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, 030104 developmental biology, Complementary and alternative medicine, 030220 oncology & carcinogenesis, biomarker, Chinese herbal medicine, Immunotherapy, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e87e18cf82928788a90008cb407d028cTest
https://doaj.org/article/622118b438a94a22b285817aece42af3Test